DGIST’s research Team has clarified the fundamentals of coiled toxin protein which causes neurodegenerative brain disorders
A research team led by Professor Sung Bae Lee of Brain and Cognitive Sciences and Professor Daehee Hwang of New Biology (Vice-head of the Plant Age and Life Research Group, IBS) has identified the early neuropathology mechanism of structural characteristics of polyglutamine toxic protein on neurodegenerative brain disorders. It was through a joint research with Professor Yuh Nung Jan at the Howards Hughes Medical Institute (HHMI) in the U.S.
The number of patients with neurodegenerative disorders is growing rapidly as humans’ life expectancy is increasing. Although many scholars are devoted into researching the pathogenesis and the advancement of neurodegenerative brain disorders, not much has been identified yet. There is still too much work left to develop an actual treatment since it is difficult to diagnose the disease early.
In this study, the researchers identified that coiled-coil structure of polyglutamine toxic protein, which is like an entangled telephone wire, causes the rapid deformation of neuron and early neurodegenerative diseases, such as Huntington’s chorea and spino-cerebellar ataxias.
Proteins have abnormal combinations with each other to form the coiled-coil structure of polyglutamine toxic protein. The research team discovered that the coiled-coil structure of polyglutamine toxic protein inside neurons cause early neuropathy by combining with ‘Foxo protein’, which is adjusts the formation of dendrite, as a transcription factor.
While the research focused on Foxo protein as the first factor of the early symptom of neurodegenerative brain disorders, it also predicted that other factors would exist. The research team thus expected to be able to speed the related studies in the future by focusing on clarifying additional factors based on this research.
Professor Lee said “The core of this research is that the coiled-coil structure of toxin protein that causes degenerative brain disorders entangle with the coiled-coil structure of other protein, which is an important cause of early neurodegenerative diseases. By developing a treatment targeting the entanglement based on coiled-coil structure through this research, we expect to be able to have effective treatments to alleviate the early symptoms of neurodegenerative brain disorders”
Learn more: A New Hope in Treating Neurodegenerative Disease
The Latest on: Neurodegenerative brain disorders
via Google News
The Latest on: Neurodegenerative brain disorders
- Neurodegenerative diseases were a factor in deaths of 42 per cent of footballers from 1965-66 seasonon November 21, 2020 at 3:10 pm
This shocking new statistic confirms professional footballers are dying of dementia at a rate of between three and four times the general population.
- Psychedelic drug triggers growth of new brain cells in miceon November 20, 2020 at 6:35 am
A new study in mice finds that one of the active ingredients of ayahuasca tea can spark the creation of new nerve cells and improve spatial learning.
- CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative diseaseon November 19, 2020 at 6:39 pm
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder. Scientists have now analyzed the effect of a point mutation that was found in three unrelated ...
- Researchers identify CLCN6 as disease gene for severe lysosomal neurodegenerative disorderon November 19, 2020 at 4:58 pm
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder. Scientists from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and the Max ...
- Cellular pathway of genetic heart disease similar to neurodegenerative diseaseon November 19, 2020 at 2:57 pm
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure. This landmark discovery found a correlation between the clumping of RNA-binding proteins long linked ...
- Research to Treat Neurodegenerative Diseases Advances: URMC Start-up Acquiredon November 18, 2020 at 11:09 am
Oscine Therapeutics – a biotechnology company that is developing cell-based therapies for neurological disorders based on discoveries made at the University of Rochester Medical Center – has been ...
- How smartphone typing patterns can track neurodegenerative diseaseon November 17, 2020 at 5:02 pm
A new study, published in the journal Chaos, is suggesting tracking changes over time in the way multiple sclerosis (MS) patients type on their smartphone touchscreens could be a useful method to ...
- Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseaseson November 16, 2020 at 5:43 am
PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new composition of matter patent by the United States Patent and ...
- Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Programon November 12, 2020 at 1:11 pm
First patient dosed in Phase 2 study of ANX005 C1q targeted mAb –SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc.
- Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with ...on November 12, 2020 at 1:07 pm
(“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the brain, body and eye, ...
via Bing News